Antacids Market

Antacids Market Outlook 2031

The global antacids market size was USD 6.60 Billion in 2022 and is expected to reach USD 9.15 Billion by 2031 expand at a significant CAGR 3.7% during the forecast period, 2023–2031. The growth of the market is attributed to the changing dietary habits. Antacids are a group of medicines which helps to neutralize the acid reflux content present inside the stomach.

They are largely used in treatment of acid indigestion, dyspepsia discomfort, stomach upset, and sour stomach. Antacids gives fast relief from heartburn. They are used for relieving the symptoms quickly because they start working in second. Antacids are present in liquid as well as in chewable tablets form and available in less price and without any prescription.

Get Free Sample Report

Growing prevalence of Gastro-Esophageal Reflux Diseases (GERD) projected to disturb the overall market over the forecast period. Based on the Gut journal, published by the International Foundation for Gastrointestinal Disorders, in 2017, the incidences of GERD was around 20% to 25% in North America, 22% in South America, 10% to 30% in the Middle East, 10% to 20% in Europe, and 5% to 7% in East Asia.

Moreover, rising awareness of GERD among people is catering the market expansion. As per article published in the International Foundation for Gastrointestinal Disorders, in November 2018, the 19^th Annual GERD Awareness Week gave information and support related to this condition. The International Foundation for Functional Gastrointestinal Disorders (IFFGD) heartens patients suffering from GERD-related symptoms, for their physician’s consultation.

However, the rising prevalence of heartburn is anticipated to hamper the market in coming years. Based on an article published in the Medical Xpress, in 2017, researchers from the University of Michigan recognized that around 21% of total U.S. population were affected by heartburn and acid reflux.

Antacids Market Trends, Drivers, Restraints, and Opportunities

• Increasing demand of early diagnosis among people, rising focus on quality of drugs, and huge production rate are anticipated to fuel the market growth over the forecast period.
• Rising awareness about early symptoms of gastrointestinal disease and increasing incidences of self-medication are driving the growth of the market.
• Inexpensive antacids and side effects of drugs such as non-steroidal and anti-inflammatory drugs are key factors fuelling the market expansion over the forecast period.
• Growing geriatric population and increasing incidences of gastroesophageal reflux disease are major factors responsible for propelling the market growth.
• Change in lifestyle, irregular dietary habits, deskbound jobs, and poor quality of sleep are projected to boost the market growth in coming years.
• Side effects of antacids such as milk-alkali syndrome, aluminum-intoxication, hypophosphatemia, constipation, osteomalacia, and dose-dependent rebound hyperacidity are expected to hamper the market growth over the forecast period.

Scope of The Antacids Market Report

The report on the global antacids market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Antacids Market Segment Insights

Tablet segment is projected to hold a major market share

On the basis of dosage form, the antacids market is divided into tablet, liquid, and others. The tablet segment is expected to hold a key share of the market during the forecast period. In the market tablets are present with many flavors to increase patient adherence on the medicine which is projected to fuel the segment growth in the coming years.

Tablets offers particular amount of dosage to the patients as compared to other forms of dosage. Also tablets are easy to store which is propelling the demand of antacids in the tablet forms.

On the other hand, the liquid segment is anticipated to expand at a rapid pace during the forecast period. Major market players such as Pfizer Inc.; GlaxoSmithKline plc.; and Dabur provides antacids in liquid form which drives the segment growth. Liquid antacids are available in flavored form. Because of this children and geriatric population prefers liquid antacids which boosts the growth of the segment.

Get Free Sample Report

Online pharmacy segment is expected to expand at a rapid pace

Based on distribution channels, the antacids market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment is expected to account for a key share of the market in the coming years owing to its easy availability and accessibility.

However, the online pharmacy segment is anticipated to expand at a rapid pace during the forecast period due to growing awareness among people. Based on survey conducted by the Alliance, in 2017, for Safe Online Pharmacies (ASOP Global), 35% of participants from Canada had bought prescription medicines from online pharmacy. People are choosing online pharmacies due to beneficial offers such as availability of drugs, price discounts, and home delivery services.

Get Free Sample Report

Asia Pacific is expected to dominate the market

On the basis of regions, the antacids market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to availability of effective treatment methods and increasing disposable income.

Moreover, high unmet clinical needs and awareness about the availability of these products among consumer are anticipated to drive the regional market growth. Also, presence of key market players such as GlaxoSmithKline plc.; Pfizer Inc.; Abbott are propelling the regional market expansion. 

However, the market of North America is expected to exhibit a rapid growth rate in the coming years owing to growing prevalence of digestive disorder along with consumer awareness about antacid products. The presence of developed countries in region is driving the regional market growth.

Get Free Sample Report

Segments

The global antacids market has been segmented on the basis of

Dosage Form

• Tablet
• Liquid
• Others

Distribution channels

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• GlaxoSmithKline plc.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dr. Reddy’s Laboratories Ltd.
• Sanofi
• Reckitt Benckiser Group plc.
• Sun Pharmaceuticals Ltd.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Procter & Gamble

Competitive Landscape

Key players competing in the antacids market include GlaxoSmithKline plc.; Bayer AG; Boehringer Ingelheim International GmbH; Dr. Reddy’s Laboratories Ltd.; Sanofi; Reckitt Benckiser Group plc.; Sun Pharmaceuticals Ltd.; Takeda Pharmaceutical Company Limited; Pfizer Inc.; and Procter & Gamble.

Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase/enhance their market shares. For instance, in 2016, Dexilant (Dexlansoprazole) was launched by Takeda Pharmaceutical Company Limited. It was company’s first approved proton pump inhibitor that uses dual delayed-release technology for GERD patients.